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INTRODUCTION
Some 75–90% of the incidence of colon cancer is
thought to be the result of environmental factors, with
diet as a major determinant. Diets high in fat and low in
fruits, vegetables and fibre are associated with a high
cancer risk.1 The effects of coffee on cancer risk have also
been scrutinized because coffee is a widely consumed
beverage. In 1991 the International Agency for Re-
search on Cancer of the World Health Organization
concluded that the collective evidence on coffee use and
colorectal cancer is compatible with a ‘protective’ effect.2
Since then, eight epidemiological studies have further
assessed coffee use in relation to colorectal cancer. The
relative risk in these latest studies varied between 0.48
and 1.0, with the exception of a relative risk of 1.2 for
men and 0.8 for woman in a Norwegian follow-up study
on coffee use and cancer development.3–10 Two studies
also assessed the risk of developing adenomas in
relation to coffee use and reported relative risks of 0.3
and 1.0, respectively.4, 7 No detailed information on the
type of coffee brew were reported in these studies. Overall
these data reinforce the possible ‘protective’ effect of
coffee on colorectal cancer found in earlier studies.
SUMMARY
Background: Epidemiologic studies suggest that coffee
use might protect against colorectal cancer. Inconsis-
tencies as to the effect of coffee use and colorectal cancer
between epidemiologic studies might be related to the
type of coffee brew.
Objective: We studied the effect of unfiltered coffee con-
sumption on putative biomarkers for colonic cancer risk.
Design: A total of 64 healthy volunteers (31 men and
33 women), with a mean age of 43  11 years were
randomly assigned to two groups in a crossover design,
with two intervention periods of 2 weeks separated by a
washout period of 8 weeks. Treatments were 1 L of
cafetie`re (French press) coffee daily or no coffee. At the
end of each intervention period, fasting blood samples,
colorectal biopsies and 48 h faeces were collected.
Results: No effect of coffee on colorectal cell prolifer-
ation, assayed by estimating the Proliferating Cell
Nuclear Antigen labelling index, was seen. Addition-
ally, no effects were seen on the concentrations of
faecal soluble bile acids and colorectal mucosal
glutathione S-transferase activity. However, unfiltered
coffee significantly increased the glutathione content
in the colorectal mucosa by 8% and in plasma by
15%. Other aminothiols in plasma also increased on
coffee.
Conclusion: Unfiltered coffee does not influence the
colorectal mucosal proliferation rate, but might increase
the detoxification capacity and anti-mutagenic proper-
ties in the colorectal mucosa through an increase in
glutathione concentration. Whether this effect indeed
contributes to a lower colon cancer risk remains to be
established.
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In a meta-analysis of coffee consumption and the risk of
colorectal cancer, three putative working mechanisms
for the protective effect of coffee were discussed: (i) the
anti-mutagenic properties of coffee have been related to
hemicellulose fibre and polyphenolics that were identi-
fied in brewed and instant coffee; these constituents
removed and destroyed mutagens in pyrolysates in
food;12 (ii) the influence on colonic motility;11 and (iii)
the influence on faecal bile acids—coffee might reduce
the hepatic excretion of bile acids and thereby lower the
risk for colon cancer.13–15 Secondary bile acids are
promoters of colon carcinogenesis in laboratory animals,
although human data are less convincing.16–19 Epide-
miological studies have shown a positive correlation
between faecal bile acid concentration and colon cancer
risk.20 Furthermore, colonic bile acids have cytotoxic
properties and can stimulate the proliferation of colonic
cells.21, 22 Measurement of the effect of coffee on faecal
bile acids might thus be useful in evaluating the
epidemiological findings on coffee and colon cancer.
A marker that might be closer to the actual process of
carcinogenesis is colonic cell hyperproliferation which is
thought to be an early event in the multi-step process of
the colonic adenocarcinoma sequence.23 Measurement
of colorectal mucosal cell proliferation parameters, such
as the labelling index and the distribution of the
proliferating cells in the crypt, have been used as end-
points in clinical trials.24 The colorectal mucosal cell
proliferation can be reduced or normalized by possible
chemopreventive agents such as calcium, resistant
starch, vitamin A, C and E, and x-3 fatty acids.22, 25–27
Animal studies on the effect of coffee in the digestive
tract have focused on the effect of coffee oil and its major
non-triacylglycerol constituents, the diterpenes cafestol
and kahweol. Coffee oil reduced the frequency of 1,2-
dimethylhydrazine induced adenocarcinomas of the
colon in rats whereas these diterpenes enhanced the
glutathione S-transferase activities of small intestine
and liver in mice and rats.28–31
The glutathione S-transferase biotransformation sys-
tem is involved in the liver metabolism and detoxifica-
tion of many xenobiotics. These enzymes are also
present in the human gastrointestinal tract.32 Dietary
components which increase their concentrations in the
gastrointestinal tract are thought to increase its detoxi-
fying capacity and might help to prevent cancer.33–36
The inconsistencies between the observational studies
suggest that either not all types of coffee brew have the
same effect on the colorectal cancer risk or that the
effect is spurious. In addition, the mechanism for
achieving colon cancer prevention is still unclear. We
therefore studied the effect of coffee on putative
biomarkers for colonic cancer in human volunteers.
We used unfiltered coffee so as to include all possible
components, such as the coffee diterpenes.37
METHODS
Subjects and design
Our primary hypothesis was that coffee intake would
decrease the proliferating cell nuclear antigen labelling
index in the colorectal mucosa. Accessory hypotheses
were that coffee would increase the glutathione
S-transferase enzyme activity and that the concentra-
tion of glutathione in the colorectal mucosa and would
decrease soluble faecal bile acids. To test this we
performed a comparative crossover study using unfil-
tered coffee in healthy volunteers. The study protocol
was approved by the local human ethics committee.
We recruited the healthy volunteers through an article
in a local paper and posters on the hospital and
university grounds. Subjects were eligible if they: drank
an average of 2–3 cups of filtered coffee per day; were
between 24 and 70 years of age, were not following a
medical diet; used no laxatives, non-steroidal anti-
inflammatory drugs, vitamin supplements or lipid-
reducing drugs; and had not used antibiotics within
2 months before entering the study. Exclusion criteria
were: a history of liver or kidney diseases (serum
alanine aminotransferase activity greater than 30 U/L
or a serum creatinine concentration above the upper
limit of normal); a history of cholecystectomy or partial
bowel resection; a serum total cholesterol greater than
6.5 mmol/L or fasting triacylglycerol greater than
3.0 mmol/L; or living more than 50 km from the
University site.
Seventy volunteers were eligible and gave their written
informed consent. They were stratified by gender and
smoking habit and then randomly assigned to the two
intervention sequences. Subjects were enrolled in three
shifts; one shift started in April, one in June and one in
September of 1997.
Subjects were instructed to maintain their usual diet
during the study. We checked compliance with a 3 days
dietary recall in each intervention period. Diet compo-
sition was calculated using the Dutch nutrient data-
base.38
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The study consisted of two intervention periods of
2 weeks each separated by a washout period of
8 weeks, in a crossover design. One group started on
1 L per day of unfiltered cafetie`re coffee, which is also
known as French Press or plunger coffee. One litre of
coffee equals six large cups. The other group did not use
coffee, but instead used water, milk, chocolate drink, tea
or broth. Each of these beverages was limited to a
maximum of three cups per day. On day 13 and 14 of
each intervention period, 48 h faeces were collected on
dry ice, and on day 15, fasting blood-samples and
colorectal biopsies were taken. During the second period
treatments were switched. All samples were coded so as
to hide the identity and treatment of subjects to
laboratory personnel. For each individual the samples
obtained in the two intervention periods were analysed
simultaneously.
Coffee preparation
We used ‘Douwe Egberts’ brand, coarsely ground coffee
(Sara Lee Company, Utrecht, the Netherlands), consist-
ing of a blend of arabica and robusta beans. This is the
most widely used coffee brand and blend in the
Netherlands. We packaged the coffee in evacuated
plastic bags in daily portions in order to preserve the
coffee aroma. Volunteers put 39 g of ground coffee into
a 1-L cafetie`re coffee-pot (Blokker, Amsterdam, the
Netherlands); 600 mL of boiling water was poured on to
the grounds as described.37 Subjects then stirred the
brew and after 5 min they pushed down the plunger to
separate the brew from the grounds. This resulted in
500 mL of cafetie`re coffee. The mean (s.d.) cafestol
concentration was 34  3 mg/L and the kahweol
concentration was 26  1 mg/L. Subjects prepared
and consumed two such 500-mL portions daily. We
advised them to drink the coffee throughout the whole
day and provided the volunteers with insulated flasks.
We considered it highly likely that the subjects were
compliant because few would enjoy drinking a large
amount of strong coffee all at once.
Colonic tissue and assays
Colorectal mucosal biopsies (six biopsies per location) of
normal tissue at 10–15 cm from the anal verge were
obtained during sigmoidoscopy without previous bowel
preparation. Three biopsies were immediately stretched
and fixated in ethanol (70% v/v) and consecutively
embedded in paraffin and stored until use for immuno-
histochemical proliferating cell nuclear antigen analy-
sis. The remaining three biopsies were immediately
frozen in liquid nitrogen and stored at –80 °C until use
for glutathione S-transferase fenotyping and glutathi-
one assay.
Proliferating cell nuclear antigen labelling. Standard histo-
logical sections of the colorectal biopsies embedded
in paraffin were prepared on slides coated with poly
L-lysine (Sigma). Sections were incubated with PC10
antibodies (Dako, Glostrup, Denmark) diluted 1:400 in
phosphate buffered saline (PBS) containing 4% bovine
serum albumin for 1 h at 25 °C, after de-paraffinization
and blocking of endogeneous peroxidase activities, as
described before.22 The binding of the PC10 antibody
was visualized with a streptavidine–biotine system
(Histostain-SP, Zymed Laboratories, San Francisco,
USA). Ten complete longitudinally sectioned crypts
(20 crypt-halves) were scored with a 40· objective.
All cells with a homogeneous and moderately or
strongly stained nucleus were counted as positive.
Epithelial cell proliferation was expressed as the total
labelling index, which is defined as the fraction of
labelled cells in the whole crypt. In addition, the crypts
were divided into five compartments to analyse the
spreading of labelling throughout the crypt. The
intra- and inter-observer correlation for estimating the
labelling index was 0.976 and 0.926, respectively.
Glutathione S-transferases and glutathione content. The
frozen biopsies were homogenized in a glass/glass
Potter–Elvehjem tube after dilution with a buffer
solution (0.25 M saccharose, 20 mM Tris, 1 mM dithio-
threitol, pH 7.4) as described before.33 Aliquots of post-
centrifugation supernatant, representing the cytosolic
fractions, were frozen in liquid nitrogen and stored at –
80 °C until use. Protein concentrations were deter-
mined in duplicate according to the method of Lowry
et al.39 Total glutathione S-transferase enzyme activity
was assayed in duplicate with 1-chloro-2,4-dinitroben-
zene (CDNB) as substrate according to Habig et al.40
Total glutathione was quantified in duplicate by high
performance liquid chromatography after reaction with
monobromobimane according to Fahey and Newton,
with minor modifications, as described before.41 Gluta-
thione S-transferase isoenzyme concentrations were
determined as follows: cytosolic samples were
subjected to sodium dodecyl sulphate-polyacrylamide
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gel and subsequently to Western blotting.42 Western
blots were stained with specific antibodies against
glutathione S-transferase Alpha, Mu and Pi, and
subsequently quantified by densitometry. The within-
assay and between-assay variation were both 5% for
glutathione S-transferase Mu and 25% for glutathione
S-transferase Alpha and Pi. Class Alpha antibodies
react against glutathione S-transferase A1-1, glutathi-
one S-transferase A1-2 and glutathione S-transferase
A2-2, class Pi antibodies recognize glutathione S-
transferase P1-1 and class Mu antibodies are directed
against glutathione S-transferase M1a-1a, glutathione
S-transferase M1a-1b and glutathione S-transferase
M1b-1b.42–44
Blood samples and assays
Fasting venous blood samples were collected on day 15
of each intervention period.
Serum cholesterol and alanine aminotransferase were
analysed in the routine clinical laboratory of our
hospital according to standard clinical chemical proce-
dures at 37 °C on a Hitachi 747 analyser (Roche
Boehringer Mannheim, Almere, the Netherlands).
EDTA-treated blood samples for analysis of glutathione,
cysteine, cysteinylglycine and total homocysteine were
immediately placed on ice until the plasma was
separated by centrifugation. EDTA-treated plasma sam-
ples were stored at –20 °C until analysis. Concentra-
tions of glutathione, cysteine, cysteinylglycine and total
homocysteine in plasma were determined by automated
reduction with NaBH4/dithiothreitol and derivitized by
Thiolyte (Calbiochem, La Jolla, USA) as described
previously.45 The inter- and intra-assay variation was
less than 5%.
Faeces
Forty-eight hour faeces were collected on dry ice,
weighted and subsequently stored at –20 °C until
processing. The thawed faeces was homogenized with
a blender and a 5-g sample was freeze dried for 48 h
(Hetosicc, Allerød, Denmark). The dry weight is the
freeze dried weight as a percentage of the wet weight.
Faecal water. Faecal water was prepared as described
previously with slight modifications.22 The homogen-
ized faecal samples were centrifuged at 40 000 g for
2 h at 4 °C. Faecal water was removed and filtered
using a 5-lm filter (Schleicher & Schuell, Dassel,
Germany) and stored at –20 °C until analysis.
Bile acid analysis. Bile acids were determined as previ-
ously described.22 In short, after enzymatic hydrolysis
the bile acids were extracted from faecal water by
SepPak C18 chromatography. The saponifiable conju-
gates were then hydrolysed at 60 °C for 2 h in 1 mL of
1 M KOH solution in methanol. After a second extrac-
tion by SepPak C18 chromatography, the unconjugated
bile acids were separated from the neutrol sterols by
Lipidex DEAP chromatography and measured after
methylation and silylation by capillary gas chromatog-
raphy (column CP Sil 5CB) on a Packard 430 gas
chromatograph.
Statistics
We designed the study to pick up an effect of coffee on
the proliferating cell nuclear antigen labelling index as a
proliferation biomarker in normal colorectal mucosa. To
pick up an effect of 10% at P < 0.05 with a power of
80% in a crossover design we required 56 subjects.
The wet and dry weight of the faeces and the faecal
soluble bile acids were analysed. The following bio-
markers were investigated in the colonic mucosa: the
proliferating cell nuclear antigen labelling index, the
glutathione S-transferase enzyme activity and
glutathione S-transferase Alpha, Pi and Mu isoenzyme
contents, as well as the glutathione content. The
glutathione, cysteine, cysteinylglycine and homocyste-
ine concentrations in plasma and the cholesterol and
alanine aminotransferase concentrations in serum
were investigated. Differences in biomarkers between
the end of the no-coffee period and the end of the coffee
period were calculated per subject and analysed by
using a two-sided unpaired t-test (SPSS Inc, Chicago,
USA).
RESULTS
A total of 64 volunteers (31 men and 33 women) with
a mean age of 43  11 years (range: 24–70 years)
completed the study. Six volunteers dropped out; one
subject stopped due to palpitations and tremor during
the first days of drinking the cafetie`re coffee; the other
five subjects resigned for reasons not related to the
study. The characteristics of the 64 volunteers who
completed the study are shown in Table 1.
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During the coffee period, in which subjects drank 1 L
of coffee daily, more water (mean 361 g) was consumed
than in the no-coffee period (Table 2). The protein
intake in the coffee period was 8 g higher than in the
no-coffee period. No other differences in reported dietary
intakes were noticed.
Coffee consumption did not affect the total proliferating
cell nuclear antigen-labelling index, the faecal soluble
bile acid concentrations, the colorectal glutathione
S-transferase enzyme activity, the glutathione S-trans-
ferase Alpha, Mu and Pi isoenzyme concentrations or
the faecal wet and dry weights (Table 3). Additionally,
no differences in the five compartmental proliferating
cell nuclear antigen-labelling indexes were seen (data
not shown).
However, the mean colorectal mucosal glutathione
concentration was 30.1 nmol/mg protein at the end of
the no-coffee period and 32.5 nmol/mg protein at the
end of the coffee period (Table 3). Plasma glutathione
increased from 5.5 lmol/L at the end of the no-coffee
period to 6.3 lmol/L at the end of the coffee period
(Table 4). We thus observed an increase in colorectal
mucosal glutathione concentration of 8% or 2.5 nmol/
mg protein (P  0.01) and in plasma glutathione
concentration of 15% or 0.8 lmol/L (P  0.003)
caused by unfiltered cafetie`re coffee. The effect of coffee
on the plasma and colorectal mucosal glutathione
concentrations were seen in both treatment sequences
(data not shown).
The concentrations of other thiols in plasma also
increased significantly on coffee (Table 4): cysteinylgly-
cine by 9% or 4.2 lmol/L (P  0.004), cysteine by 3%
or 7.7 lmol/L (P  0.004) and homocysteine by 10%
or 12.8 lmol/L (P  0.001).
As expected, consumption of unfiltered coffee increased
mean serum cholesterol by 10% or 0.5 mmol/L (95%
CI: 0.3–0.6, P < 0.001) and serum alanine amino-
transferase activity by 2.5 U/L (95% CI: 1.0–3.9,
P  0.001).37 In three of the subjects the alanine
aminotransferase activity exceeded the upper normal
reference level after 2 weeks of drinking coffee; in one
subject this was observed at the end of the no-coffee
period. Alanine aminotransferase activity returned to
normal within 2–3 weeks in all but one subject, in
whom values were normalized only after 9 months
(data not shown).
DISCUSSION
We found that drinking 1 L of unfiltered coffee every
day for 2 weeks did not affect the colorectal cell
proliferation. The crossover design of our study and
the distribution of subjects over three shifts eliminate
chance fluctuations and seasonal influences as con-
founding factors. These results thus do not reinforce the
hypothesis that coffee consumption reduces the risk of
Table 1. Baseline characteristics of the healthy volunteers who
took part in this comparative crossover study of the influence of
unfiltered coffee on biomarkers for colonic cancer
Total no. volunteers 64
No. men:women 31:33
No. smokers 16
Age (years  s.e.) 43.4  1
Age range (years) 24–70
Body-mass index (kg/m2) 24.5  0.5
Cholesterol (mmol/L) 5.0  0.1
Triacylglycerol (mmol/L) 1.0  0.1
Alanine aminotransferase (U/L) 13.0  0.6
Creatinine (lmol/L) 86.8  1.4
Table 2. Average dietary intakes of the 64
healthy volunteers who took part in this
comparative crossover study comparing a
1 L coffee period with a no-coffee period
No coffee
period
Coffee
period Difference
95% CI of
difference
Energy (MJ/day) 10.1 10.1 0.1 )0.5 to 0.5
Fat (g/day) 96 97 1 )6 to 9
Protein (g/day) 85 93 8  2 to 13
Carbohydrates (g/day) 278 270 )8 )23 to 7
Fibre (g/day) 19 19 0 )2 to 1
Water (g/day)* 2519 2880 361  195 to 527
CI, confidence interval.
Three-day dietary recall data were collected in both intervention periods.
* The amount of water included beverages as well as the water in solid foods.
  P < 0.05.
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colon cancer. However, by themselves our findings on
proliferation are insufficient to refute the epidemiolog-
ical findings on coffee and prevention of colon cancer.
Our findings might also indicate that the influence of
coffee on colon cancer risk might act through pathways
other than those influencing the cell proliferation rate.
Colorectal cancer may arise when the balance between
cell proliferation and apoptosis is disrupted in favour of
uncontrolled growth.46 Most research on colon cancer
has focused on the molecular regulators of cell-cycle
progression and proliferation, but defective apoptosis
may also be involved.47 Therefore, factors which
influence colonic carcinogenesis in a beneficial way,
might not have an effect on colonic cell proliferation.48
An alternative explanation for the lack of effect on
proliferating cell nuclear antigens could be that it might
be difficult to (further) decrease the ‘normal’ cell
proliferation rate in healthy volunteers. However, we
found a wide range of proliferating cell nuclear antigen
values in these normal subjects, and therefore we find
this explanation unlikely.
Secondary faecal soluble bile acids which can stimulate
colonic cell proliferation, were also investigated. The
accessory hypothesis that we tested was that unfiltered
coffee decreases the faecal soluble bile acid concentra-
tion. In line with the results on colorectal mucosal
proliferating cell nuclear antigen labelling index, the
total faecal soluble bile acid concentration as well as the
Table 4. Plasma thiols in volunteers receiving 1 L of unfiltered coffee or no-coffee, daily, for 2 weeks each, in this crossover study
Number of
subjects
No-coffee period
Mean  s.d.
Coffee period
Mean  s.d. Difference
95% CI of
difference
Glutathione (lmol/L) 45 5.5  1.8 6.3  1.4 0.8  0.3 to 1.4
Cysteinylglycine (lmol/L) 63 46.8  7.9 51.0  8.3 4.2à 1.4 to 6.9
Cysteine (lmol/L) 63 209.8  23.4 217.5  21.8 7.7à 2.5 to 13.0
Homocysteine (lmol/L) 63 12.8  3.3 14.0  3.5 1.2* 0.5 to 1.9
CI, confidence interval.
* P = 0.001;   P = 0.003; à P = 0.004.
Table 3. Faecal and colorectal mucosal biomarkers for colonic cancer in the volunteers receiving 1 L unfiltered coffee or no-coffee,
daily, for 2 weeks each, in this crossover study
Number of
subjects
No-coffee period
mean  s.d.
Coffee period
mean  s.d. Difference
95% CI of
difference
Faeces
wet weight (g/48 h) 64 323  159 337  184 14 )28 to 58
dry weight (%) 64 25  5 24  4 )1 )2 to 1
Soluble faecal bile acids in faecal water
total (lmol/L) 63 170  207 138  117 )32 )83 to 17
secondary (lmol/L) 63 126  126 111  103 )15 )39 to 9
Colorectal mucosa
Glutathione S-transferase biotransformation system
GST activity (nmol/min/mg protein) 62 211  67 210  70 )1.0 )23 to 20
GST isoenzymes (ng/mg protein)
GST Alpha 59 30.2  9.0 34.5  10.1 4.3 )4.1 to 12.7
GST Mu 60 618  98 644  104 26 )62 to 116
GST Pi 59 2017  59 2157  124 140 )98 to 377
Glutathione (nmol/mg protein) 62 30.1  6.6 32.5  6.5 2.5* 0.5 to 4.4
Cell proliferation
PCNA-labelling index (%) 58 21.0  1.2 19.7  1.1 )1.2 )4.0 to 1.5
Number of subjects: due to lack of sufficient material not all assays could be performed on all 64 subjects.
CI, confidence interval; GST, glutathione S-transferase; PCNA, proliferating cell nuclear antigen.
* P = 0.01.
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cytotoxic secondary faecal soluble bile acid concentra-
tion did not change between the intervention periods
(Table 3). Therefore, the cytotoxic secondary bile acids
do not seem to be involved in the putative protective
effect of coffee in colonic cancer development.
The hypotheses that coffee would increase the
glutathione S-transferase activity and the glutathione
concentration in the colorectal mucosa were partly
confirmed. Animal studies have found that coffee oil and
its constituents, the diterpenes cafestol and kahweol,
induced intestinal glutathione S-transferase enzyme
activity; glutathione content has not been investi-
gated.29–31 The amount of coffee constituents fed in
animal studies was much higher than can be achieved
in humans drinking coffee. This might explain why we
did not find an induction of glutathione S-transferase
enzyme activity or glutathione S-transferase isoenzyme
concentrations in the colorectal mucosa. However,
unfiltered coffee did increase colorectal glutathione
concentration by 8% and plasma glutathione concen-
tration by 15% (Tables 3 and 4). It is unlikely that this
was caused by the slightly higher protein intake during
the coffee period (Table 2). We are not aware of
experimental data on the effect of protein intake on
plasma glutathione concentrations in man, but earlier
findings on the relation between protein intake and
plasma homocysteine concentrations show that the
effect of small differences in protein intake are negli-
gible.49–51 We therefore assume that the rises in
glutathione and other thiols in plasma (Table 4) were
also caused by substances in the coffee rather than by
minor differences in protein intake.52
Normal colonic epithelium is a rapidly proliferating
tissue because renewal of the colonic epithelium takes
place every 4–6 days. Such rapidly proliferating cells
are more sensitive to toxic compounds and mutagenic
changes and therefore to malignant transformation,
which is in essence a specific series of mutations.53
Glutathione might inhibit this process through several
mechanisms. First, intracellular glutathione protects the
cell from DNA damage by mutagenic compounds and
xenobiotics. This detoxifying capacity involves enzy-
matic as well as non-enzymatic processes. Glutathione
reacts non-enzymatically with some mutagenic com-
pounds such as hydroxyl radicals, but requires gluta-
thione S-transferase enzymatic catalysis to detoxify
reactive electrophilic xenobiotic.54–58 The newly formed
compounds are more water soluble and less toxic than
the original compound and can be excreted more easily
through the bile and urine.59 This is confirmed by
studies in cultured human lymphoblastoid cells, in
which the frequency of both spontaneous and long
wavelength ultraviolet-induced mutations at the hypo-
xanthine guanine phosphoribosyl transferase locus can
be enhanced at least fivefold by depletion of glutathione.
Reactive intermediates, such as toxic compounds and
xenobiotics, normally quenched out by glutathione,
appeared to be partly responsible for this effect.60
A second mechanism may involve DNA repair. A
decrease in glutathione concentration by buthionine
sulfoximine, a specific inhibitor of c-glutamylcysteine
synthetase, inhibited DNA repair in cisplatin-resistant
human ovarian cancer cells. Treatment of cells with
glutathione esters after buthionine sulfoximine resulted
in a complete recovery of DNA repair enzyme activity.61
Furthermore, glutathione is a cofactor in the synthesis
of DNA precursors, especially the deoxyribonucleotide
triphosphates.62, 63
A third potential working mechanism of glutathione
lies in the possible role of mitochondrial glutathione
homeostasis in the direct regulation of apoptosis.64–66
Thus there are a number of mechanisms that may link
the rise in colorectal mucosal glutathione observed by
us with the epidemiologically observed inverse associ-
ation between coffee intake and colon cancer. One
important question that remains is whether the effect
on glutathione and the other thiol components was
caused by substances present only in unfiltered coffee
such as used by us, or by factors that are also present in
filtered coffee. Future studies may answer this question.
Coffee induces the motor activity in the colon in 60%
of healthy volunteers.67 The magnitude of this motor
activity induction by 240 mL coffee is similar to that of
a meal.68 The speed of the response, within 4 min of
ingestion, suggests that coffee may induce a ‘gastroco-
lonic’ response.11, 67 Colonic motility could be related to
colonic cancer risk by the influence on the exposure of
the epithelia to colonic contents. We did not find
changes in the wet and dry weight on coffee. Therefore
we conclude that an increased motility on coffee seems
not to be responsible for the putative protective effect of
coffee in colonic cancer development.
Coffee consumption in most populations varies from
one to seven cups per day which is less than the six
‘large’ and strong cups used in our study.69 Thus our
results only apply to heavy coffee drinkers.
We conclude that unfiltered coffee does not influence
the colorectal mucosal proliferation rate, but intake of
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large amounts might locally increase the detoxification
capacity and anti-mutagenic properties in the colorectal
mucosa through an increase in glutathione concentra-
tion. Whether this effect indeed contributes to a lower
colon cancer risk remains to be established.
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